Seeking Alpha

Prohost Biotech  

View Prohost Biotech's Comments BY TICKER:

  • Agenus Offers An Investment Opportunity [View article]
    Adam is a great guy. Let him do whatever he wishes as long as he is happy and makes some people around him and following him happy too . Those who got hurt by what he wrote or said are rather more frustrated of themselves than hurt by Adam. They know well that their anger against the man is in fact against their picks failure and against themselves because they failed to select better firms. Adam, they know cannot by himself paralyze a stock and kill its giant company unless the giant is no giant but a victim of a morbid obesity.
    Feb 8, 2014. 08:23 PM | Likes Like |Link to Comment
  • Agenus And Glaxo: Sizing Up The Potential For The RTS,S Malaria Vaccine [View article]
    Thanks for the excellent article. It said it all about malaria and the difficult path for vaccination aimed at protecting against the horrible complication of the disease. The explication in the article of the role the first promising vaccine is expected to play among other measures aimed at protecting and preventing against malaria is extremely useful.
    Oct 10, 2013. 09:24 AM | 3 Likes Like |Link to Comment
  • Agenus Offers An Investment Opportunity [View article]
    Yes. the results are very encouraging and bring hope to the patients, their physicians, the company's scientists behind the vaccine and Agenus' shareholders. Until now, clinical trial results are demonstrating that Prophage Series G-100 is safe and effective against a brain cancer that has yet to succumb to a treatment. Now we have to continue hoping that the regulators get excited about the results and guide Agenus, regardless of its size, to get the vaccine to cross the final bridge into the market. Hopeless people on the other side of the bridge, are anxiously waiting to be saved.
    Sep 17, 2013. 09:06 PM | Likes Like |Link to Comment
  • Agenus Offers An Investment Opportunity [View article]
    Investors have to proceed with caution anyway as long as they are dealing with Wall Street democracy. However, common sense mixed with facts dictates situations where extra-cautious investors keep missing. Our statistics from our Newsletter readers demonstrate that many investors have missed stocks that rallied from under $15 to over $120 because of their caution. They missed opportunities provided by PCYC, AMGN, VRTX, REGN and plenty of other small and medium size firms whose stocks have quadrupled or more in the past one and two years. Indeed, caution is important but should also be based on studies and following up on the firms from a near distance, and direct communication rather from far away. One cannot blindly believe all that's posted on the Internet. Due diligence yes, should be made before deciding to express extreme caution based on past history in one area of the firms' lives.
    Sep 12, 2013. 02:25 PM | 2 Likes Like |Link to Comment
  • Agenus Offers An Investment Opportunity [View article]

    Thanks for the observation, which is correct. As a matter of fact, we did mention herpV as a genital herpes vaccine in the beginning, as we were mentioning the upcoming catalysts. We wrote, "Phase 2 data for HerpV, Agenus'QS-21 Stimulon containing investigational therapeutic vaccine for genital herpes, during the fourth quarter of 2013." the mistake was made as we tried and meant to mention the fact that unlike the HPV vaccines on the market, HerpV is therapeutic, not preventive." So, the misleading statement happened in this part and we thank you for clarification, which was really necessary and important.'
    Sep 8, 2013. 02:20 PM | Likes Like |Link to Comment
  • Agenus: Assessing Stock Prospects After MAGE A-3 Cancer Vaccine Misses Primary Endpoint In Melanoma [View article]
    Alp. We are curious to know why cancer vaccine is a hype? Are cancer immuno-therapeutics that have demonstrated safety and superior efficacy in cancer considered hype also? If so, can you explain? Unless your remark is based on previous failures of therapeutic vaccines. If this is the reason, then it is invalid as we know now much better about the immune system, its cells and antibodies, the antigen used and the adjuvant added more than any other time in the past. The science and knowledge behind the development of immuno-stimulants, modulators and other facts are solid and validated. This is true unless something that you know that scientists don't. In this case we would love to know it and we will appreciate it.
    Sep 5, 2013. 04:40 PM | 7 Likes Like |Link to Comment
  • Agenus Continues to Outperform [View article]
    Believe it or not, I am very lucky betting on horses based on their external appearances. I go to the race track maybe twice a year only. I don't even know the names of the horses running. All I know is their numbers. I won each and every time. Some people believe, though that betting without having a clue about the horse, or the number they blindly pick at a casino roulette has only one name: Gambling. Indeed, I gamble once every 6 months and believe it or not I win. Is this something?
    Jul 24, 2013. 03:04 PM | Likes Like |Link to Comment
  • Agenus Continues to Outperform [View article]
    We appreciate the work of Genocea and we never said it is bad or will not succeed. All we said is that we need more data from Genocea to be able to confirm our impression that it is, indeed, on the road towards developing successful therapeutic vaccines. We know well the reasons of failure of other therapeutic vaccines and we know that therapeutic vaccines will reach the market and will be added to Dendreon's vaccine Provenge. As we wrote to one of our readers, "companies developing therapeutic vaccines should not be put in a race against each other. The more the number of vaccine successes, the increased the number of vaccines approved."
    Jul 10, 2013. 04:34 PM | Likes Like |Link to Comment
More on AGEN by Prohost Biotech